Related content

Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (''draw-back'' therapy)

By Tahara M.   Matsuoka T.   Yokoi T.   Tasaka K.   Kurachi H.   Murata Y.  

Fertility and Sterility, Vol. 73, Iss. 4, 2000-04 ,pp. : 799-804

Elsevier

Access to resources Recommend Favorite

Gonadotropin-releasing hormone agonist plus ''add-back'' hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial

By Franke H.R.   van de Weijer P.H.M.   Pennings T.M.M.   van der Mooren M.J.  

Fertility and Sterility, Vol. 74, Iss. 3, 2000-09 ,pp. : 534-539

Elsevier

Access to resources Recommend Favorite

Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial

By Vercellini P.   Trespidi L.   Zaina B.   Vicentini S.   Stellato G.   Crosignani P.G.  

Fertility and Sterility, Vol. 79, Iss. 6, 2003-06 ,pp. : 1390-1395

Elsevier

Access to resources Recommend Favorite

Combined use of a long-acting gonadotropin-releasing hormone agonist and low-dose danazol in advanced stage endometriosis

By Ugur M.   Senoz S.   Gokmen O.  

European Journal of Obstetrics and Gynecology and Reproductive Biology, Vol. 68, Iss. 1, 1996-09 ,pp. : 155-158

Elsevier

Access to resources Recommend Favorite

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

By Surrey E.S.   Silverberg K.M.   Surrey M.W.   Schoolcraft W.B.  

Fertility and Sterility, Vol. 78, Iss. 4, 2002-10 ,pp. : 699-704

Elsevier

Access to resources Recommend Favorite